DRDO's 1st batch of anti-Covid drug 2DG launched
The 2DG molecule helps in the faster recovery of hospitalised patients and reduces supplemental oxygen dependence.
The Union defence minister Rajnath Singh and Union health minister Dr. Harsh Vardhan released the first batch of anti-Covid drug 2DG. The drug will help Corona patients reduce oxygen dependency.
It is an anti-Covid-19 therapeutic application of the drug 2-deoxy-D-glucose (2-DG) developed by INMAS, a lab of DRDO, in collaboration with Dr. Reddy’s Laboratories (DRL), Hyderabad.
Earlier the Drugs Controller General of India (DGCI) had approved the oral drug for emergency use as an adjunct therapy in moderate to severe coronavirus patients.
The clinical trial results of the drug showed that this molecule helps in the faster recovery of hospitalised patients and reduces supplemental oxygen dependence.
A higher proportion of patients treated with 2-DG showed RT-PCR negative conversion in Covid patients. The drug will be of immense benefit to the people suffering from Covid-19.
“I am happy to say that the Medical Corps has also decided to reintroduce its retired doctors so that our health system can be strengthened further. I heartily commend such physicians who are joining this campaign even after retiring from service,” said Rajnath Singh on the launch of the drug.
Developed by DRDO & DRL, 2-deoxy-D-glucose (2-DG) will prove effective against Covid-19. This is a great example of the scientific prowess of our country.
I congratulate DRDO & all the institutions involved in the R&D of this drug, on my behalf: Defence Minister @rajnathsingh pic.twitter.com/rp2N2keTXm
— Prasar Bharati News Services पी.बी.एन.एस. (@PBNS_India) May 17, 2021